Methotrexate therapy for ectopic pregnancy in adolescents

Area of Science:

• Reproductive Endocrinology
• Gynecology
• Pharmacology

Background:

• Ectopic pregnancy poses significant risks, particularly in adolescent populations.
• Methotrexate (MTX) is a chemotherapeutic agent used in treating ectopic pregnancies.
• Assessing MTX efficacy and suitability in adolescents is crucial for non-surgical management.

Purpose of the Study:

• To evaluate the efficacy and suitability of methotrexate (MTX) therapy for adolescent patients diagnosed with ectopic pregnancy.
• To compare treatment outcomes and protocol compliance between adolescent and adult patients receiving MTX therapy.

Main Methods:

• A study group of 55 adolescent patients with ectopic pregnancy received intramuscular MTX (50 mg/m2).
• Quantitative beta-hCG levels were monitored on days 1, 4, and 7 post-treatment, and weekly thereafter until levels fell below 15 mIU/ml.
• Treatment success was defined as achieving a beta-hCG level < 15 mIU/ml without surgical intervention; outcomes were compared to 186 adult patients.

Main Results:

• 85% of all patients achieved treatment success without requiring surgical intervention.
• While surgical intervention rates were slightly higher and success rates slightly lower in adolescents, these differences were not statistically significant (p = .71).
• Compliance rates were comparable between adolescent and adult groups, with no statistically significant differences observed (p = .17).

Conclusions:

• Methotrexate (MTX) therapy is a satisfactory and effective treatment option for adolescent patients with ectopic pregnancy.
• Adolescent patients are capable of adhering to the rigorous protocol requirements associated with MTX therapy.
• MTX offers a viable non-surgical management approach for ectopic pregnancies in adolescents.